Assetmark Inc. Reduces Stock Position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Assetmark Inc. decreased its position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 3.3% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 40,537 shares of the company’s stock after selling 1,384 shares during the quarter. Assetmark Inc. owned approximately 0.09% of Amphastar Pharmaceuticals worth $1,175,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the company. Signaturefd LLC raised its holdings in Amphastar Pharmaceuticals by 147.7% in the 1st quarter. Signaturefd LLC now owns 872 shares of the company’s stock worth $25,000 after purchasing an additional 520 shares in the last quarter. IFP Advisors Inc purchased a new position in shares of Amphastar Pharmaceuticals during the first quarter valued at about $34,000. GF Fund Management CO. LTD. bought a new position in Amphastar Pharmaceuticals in the fourth quarter worth about $38,000. GAMMA Investing LLC lifted its holdings in Amphastar Pharmaceuticals by 46.6% in the first quarter. GAMMA Investing LLC now owns 1,333 shares of the company’s stock worth $39,000 after buying an additional 424 shares during the period. Finally, Tower Research Capital LLC TRC lifted its holdings in Amphastar Pharmaceuticals by 43.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,145 shares of the company’s stock worth $43,000 after buying an additional 348 shares during the period. Hedge funds and other institutional investors own 65.09% of the company’s stock.

Amphastar Pharmaceuticals Trading Down 1.8%

NASDAQ:AMPH opened at $20.95 on Friday. The firm has a market capitalization of $987.58 million, a P/E ratio of 7.59 and a beta of 0.72. The company has a debt-to-equity ratio of 0.80, a current ratio of 2.95 and a quick ratio of 2.02. Amphastar Pharmaceuticals, Inc. has a one year low of $20.43 and a one year high of $53.96. The company’s 50-day simple moving average is $23.84 and its 200 day simple moving average is $27.00.

Analysts Set New Price Targets

A number of research analysts have weighed in on the company. JPMorgan Chase & Co. reiterated a “neutral” rating and set a $30.00 target price (down previously from $45.00) on shares of Amphastar Pharmaceuticals in a report on Monday, May 12th. Needham & Company LLC reaffirmed a “hold” rating on shares of Amphastar Pharmaceuticals in a research note on Thursday, April 10th. Finally, Wells Fargo & Company decreased their price objective on Amphastar Pharmaceuticals from $40.00 to $35.00 and set an “overweight” rating for the company in a report on Thursday, May 8th. Four analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $32.33.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.